Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial
The study aimed to determine the effect of the activated protein C on the course of systemic inflammation in the APCAP (activated protein C in acute pancreatitis) trial where we randomized 32 patients with severe acute pancreatitis to receive either recombinant activated protein C (drotrecogin alfa...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | International Journal of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2012/712739 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567969291436032 |
|---|---|
| author | Lea Kyhälä Panu Mentula Leena Kylänpää Eeva Moilanen Pauli Puolakkainen Ville Pettilä Heikki Repo |
| author_facet | Lea Kyhälä Panu Mentula Leena Kylänpää Eeva Moilanen Pauli Puolakkainen Ville Pettilä Heikki Repo |
| author_sort | Lea Kyhälä |
| collection | DOAJ |
| description | The study aimed to determine the effect of the activated protein C on the course of systemic inflammation in the APCAP (activated protein C in acute pancreatitis) trial where we randomized 32 patients with severe acute pancreatitis to receive either recombinant activated protein C (drotrecogin alfa activated) (n=16) or placebo (n=16) for 96 hours. In the present study, we present the time course of the patients’ plasma or serum levels of soluble markers (IL-8, IL-6, IL-10, IL-1ra, sE-selectin, PCT) and monocyte and neutrophil cell surface (CD11b, CD14, CD62L, HLA-DR) markers of systemic inflammatory response during the first 14 days after the randomization. The results of the intervention and placebo groups were comparable showing that recombinant APC treatment did not alter the course of systemic inflammation in severe acute pancreatitis. Our finding is in accordance with the clinical findings in the APCAP trial indicating that the intervention did not affect evolution of multiple organ dysfunctions. |
| format | Article |
| id | doaj-art-d8375a746f3a4fa091065bf4199fb72c |
| institution | Kabale University |
| issn | 2090-8040 2042-0099 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Inflammation |
| spelling | doaj-art-d8375a746f3a4fa091065bf4199fb72c2025-02-03T01:00:10ZengWileyInternational Journal of Inflammation2090-80402042-00992012-01-01201210.1155/2012/712739712739Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP TrialLea Kyhälä0Panu Mentula1Leena Kylänpää2Eeva Moilanen3Pauli Puolakkainen4Ville Pettilä5Heikki Repo6Department of Surgery, Helsinki University Central Hospital, 00029 Helsinki, FinlandDepartment of Surgery, Helsinki University Central Hospital, 00029 Helsinki, FinlandDepartment of Surgery, Helsinki University Central Hospital, 00029 Helsinki, FinlandThe Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, 33521 Tampere, FinlandDepartment of Surgery, Helsinki University Central Hospital, 00029 Helsinki, FinlandIntensive Care Units, Department of Anesthesia and Intensive Care Medicine, Helsinki University Central Hospital, 00029 Helsinki, FinlandDepartment of Medicine, University of Helsinki, 00029 Helsinki, FinlandThe study aimed to determine the effect of the activated protein C on the course of systemic inflammation in the APCAP (activated protein C in acute pancreatitis) trial where we randomized 32 patients with severe acute pancreatitis to receive either recombinant activated protein C (drotrecogin alfa activated) (n=16) or placebo (n=16) for 96 hours. In the present study, we present the time course of the patients’ plasma or serum levels of soluble markers (IL-8, IL-6, IL-10, IL-1ra, sE-selectin, PCT) and monocyte and neutrophil cell surface (CD11b, CD14, CD62L, HLA-DR) markers of systemic inflammatory response during the first 14 days after the randomization. The results of the intervention and placebo groups were comparable showing that recombinant APC treatment did not alter the course of systemic inflammation in severe acute pancreatitis. Our finding is in accordance with the clinical findings in the APCAP trial indicating that the intervention did not affect evolution of multiple organ dysfunctions.http://dx.doi.org/10.1155/2012/712739 |
| spellingShingle | Lea Kyhälä Panu Mentula Leena Kylänpää Eeva Moilanen Pauli Puolakkainen Ville Pettilä Heikki Repo Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial International Journal of Inflammation |
| title | Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial |
| title_full | Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial |
| title_fullStr | Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial |
| title_full_unstemmed | Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial |
| title_short | Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial |
| title_sort | activated protein c does not alleviate the course of systemic inflammation in the apcap trial |
| url | http://dx.doi.org/10.1155/2012/712739 |
| work_keys_str_mv | AT leakyhala activatedproteincdoesnotalleviatethecourseofsystemicinflammationintheapcaptrial AT panumentula activatedproteincdoesnotalleviatethecourseofsystemicinflammationintheapcaptrial AT leenakylanpaa activatedproteincdoesnotalleviatethecourseofsystemicinflammationintheapcaptrial AT eevamoilanen activatedproteincdoesnotalleviatethecourseofsystemicinflammationintheapcaptrial AT paulipuolakkainen activatedproteincdoesnotalleviatethecourseofsystemicinflammationintheapcaptrial AT villepettila activatedproteincdoesnotalleviatethecourseofsystemicinflammationintheapcaptrial AT heikkirepo activatedproteincdoesnotalleviatethecourseofsystemicinflammationintheapcaptrial |